The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 2012;30(2):810-8.
. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.
. Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction. J Immunol Res 2014;2014:473765.
. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs 2012;30(2):803-7.
. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol 2012;55(4):367-9.
. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.
. Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. Exp Ther Med 2014;8(6):1906-1908.
. Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. Mediators Inflamm 2015;2015:942948.
. JCV+ Patients with Inflammatory bowel disease show elevated plasma levels of MIG and SCF. Inflamm Bowel Dis 2012;18(6):1194-6.
. Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol. J Clin Endocrinol Metab 2014;99(4):E659-64.
. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Invest New Drugs 2012;30(1):405-7.
.